What is Advanced Silicon Group?
Founded in 2015, Advanced Silicon Group operates at the intersection of nanotechnology and medical diagnostics. The company specializes in the development and commercialization of novel biosensors underpinned by patented silicon nanowire technology. This technical architecture allows for unprecedented sensitivity in molecular detection, offering significant advantages over traditional diagnostic platforms. Headquartered in Massachusetts, the firm occupies a critical niche in the hardware-enabled biotech sector, where its ability to scale manufacturing of silicon-based sensors is essential for meeting the growing demand for rapid, point-of-care testing solutions. The company's market position is bolstered by its deep integration into the regional innovation ecosystem, allowing it to bridge the gap between academic research and industrial application.
How much funding has Advanced Silicon Group raised?
Advanced Silicon Group has raised a total of $1M across 1 funding round:
Angel/Seed
$1M
Angel/Seed (2021): $1M with participation from SideCar Angels, Cherrystone Angel Group, and MIT Alumni Angels of Northern California
Key Investors in Advanced Silicon Group
SideCar Angels
A Boston-based angel group that collaborates with top-tier venture capitalists to provide early-stage capital to emerging companies.
Cherrystone Angel Group
An investment firm focused on early-stage companies in New England, providing both capital and industry expertise across life sciences and healthcare.
MIT Alumni Angels of Northern California
An investment network comprised of MIT alumni that supports high-potential startups through early-stage funding and mentorship.
What's next for Advanced Silicon Group?
With the recent capital injection, Advanced Silicon Group is expected to prioritize the scaling of its manufacturing capabilities and the expansion of its commercial footprint. The strategic focus will likely shift toward securing regulatory milestones and establishing partnerships with major healthcare providers to integrate its silicon nanowire biosensors into clinical workflows. As the company moves beyond its initial development stage, the focus will remain on optimizing production yields and demonstrating the long-term reliability of its sensor arrays in real-world diagnostic environments. This trajectory suggests a move toward Series-level scaling, where the firm will need to prove the scalability of its hardware to sustain long-term growth and market penetration.
See full Advanced Silicon Group company page
